Cationic antimicrobial peptides as novel cytotoxic agents for cancer treatment

Jamie S. Mader, David W. Hoskin

Research output: Contribution to journalReview articlepeer-review

387 Citations (Scopus)

Abstract

Cancer treatment by conventional chemotherapy is hindered by toxic side effects and the frequent development of multi-drug resistance by cancer cells. Cationic antimicrobial peptides (CAPS) are a promising new class of natural-source drugs that may avoid the shortcomings of conventional chemotherapy because certain CAPs exhibit selective cytotoxicity against a broad spectrum of human cancer cells, including neoplastic cells that have acquired a multi-drug-resistant phenotype. Tumour cell killing by CAPS is usually by a cell membrane-lytic effect, although some CAPS can trigger apoptosis in cancer cells via mitochondrial membrane disruption. Furthermore, certain CAPS are potent inhibitors of blood vessel development (angiogenesis) that is associated with tumour progression. This article reviews the mechanisms by which CAPS exert anticancer activity and discusses the potential application of selected CAPS as therapeutic agents for the treatment of human cancers.

Original languageEnglish
Pages (from-to)933-946
Number of pages14
JournalExpert Opinion on Investigational Drugs
Volume15
Issue number8
DOIs
Publication statusPublished - Aug 2006

Bibliographical note

Funding Information:
J Mader was supported by a Graduate Studentship from the Nova Scotia Health Research Foundation.

ASJC Scopus Subject Areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Cationic antimicrobial peptides as novel cytotoxic agents for cancer treatment'. Together they form a unique fingerprint.

Cite this